Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1858435 | 0.91 | SMN1; SMN2 (0.41) | SMN1; SMN2GAAALDH1A1NPSR1MAPT | |
| SCHEMBL14963199 | 0.78 | KDM4E (0.53) | SMN1; SMN2GAAALDH1A1MAPTUSP2 | |
| SCHEMBL2490865 | 0.77 | — | — | |
| SCHEMBL5607056 | 0.75 | NPSR1 (0.46) | SMN1; SMN2NPSR1MAPTTDP1ACHE | |
| SCHEMBL11755388 | 0.75 | NPSR1 (0.46) | SMN1; SMN2NPSR1MAPTTDP1ACHE | |
| SCHEMBL11755378 | 0.75 | NPSR1 (0.46) | SMN1; SMN2NPSR1MAPTTDP1ACHE | |
| SCHEMBL14099841 | 0.74 | SMN1; SMN2 (0.41) | SMN1; SMN2GAAALDH1A1NPSR1MAPT | |
| SCHEMBL31518851 | 0.73 | ALDH1A1 (0.41) | SMN1; SMN2GAAALDH1A1MAPTUSP2 | |
| SCHEMBL3295915 | 0.73 | KDM4E (0.64) | SMN1; SMN2GAAALDH1A1MAPTUSP2 | |
| SCHEMBL757145 | 0.73 | SLC6A3 (0.47) | ACHETSHRSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673890-B2 | 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-18 | — | — | US | disclosed |
| US-8673890-B2 | 2,3-dihydro-1H-isoindol-1-imine derivatives useful as thrombin PAR-1 receptor antagonist | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-18 | — | — | US | disclosed |
| US-20120004476-A1 | Fullerene Derivatives and Organic Electronic Device Comprising the Same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-01-05 | — | — | US | disclosed |
| US-20120004476-A1 | Fullerene Derivatives and Organic Electronic Device Comprising the Same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-01-05 | — | — | US | disclosed |
| US-20120004476-A1 | Fullerene Derivatives and Organic Electronic Device Comprising the Same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-01-05 | — | — | US | disclosed |
| EP-2392555-A2 | FULLERENE DERIVATIVES AND ORGANIC ELECTRONIC DEVICE COMPRISING THE SAME | Korea Research Institute of Chemical Technology (KRICT) (KR) | 2011-12-07 | — | — | EP | disclosed |
| US-20110105490-A1 | 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-20110105490-A1 | 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| US-5583261-A | FOR APPLICATION TO PLANTS TO TREAT POWDERY MILDEW | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1996-12-10 | — | — | US | disclosed |
| US-5464873-A | Antigrowth agents | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-11-07 | — | — | US | disclosed |
| EP-0650471-A1 | ALICYCLIC DIAMINE FUNGICIDES | BTG INTERNATIONAL LIMITED (GB) | 1995-05-03 | — | — | EP | disclosed |
| WO-1993024444-A1 | ALICYCLIC DIAMINE FUNGICIDES | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1993-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105490-A1 | 2,3-DIHYDRO-1H-ISOINDOL-1-IMINE DERIVATIVES USEFUL AS THROMBIN PAR-1 RECEPTOR ANTAGONIST | F2R, F2RL1, F2RL3 | SMN1; SMN2 3382/4885GAA 4443/4885ALDH1A1 1921/4885 |
| US-20120004476-A1 | Fullerene Derivatives and Organic Electronic Device Comprising the Same | SCO2, VDAC2, TRPA1 | SMN1; SMN2 3736/4885GAA 4630/4885ALDH1A1 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.